GlaxoSmithKline (LON:GSK) Stock Rating Reaffirmed by Shore Capital

Share on StockTwits

GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating restated by equities researchers at Shore Capital in a research note issued on Wednesday, ThisIsMoney.Co.Uk reports.

Several other brokerages have also commented on GSK. Kepler Capital Markets upped their price objective on shares of GlaxoSmithKline from GBX 1,440 ($18.82) to GBX 1,540 ($20.12) and gave the stock a “hold” rating in a report on Tuesday, June 11th. HSBC set a €16.50 ($19.19) price objective on shares of UniCredit and gave the stock a “buy” rating in a report on Tuesday, May 14th. Liberum Capital restated a “hold” rating on shares of Daily Mail and General Trust P L C in a report on Tuesday, July 2nd. Credit Suisse Group began coverage on shares of Regeneron Pharmaceuticals in a report on Monday, May 20th. They issued a “neutral” rating and a $336.00 price objective on the stock. Finally, Jefferies Financial Group restated a “buy” rating and issued a C$15.00 price objective on shares of Aphria in a report on Friday, May 24th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of GBX 1,535.88 ($20.07).

Shares of GSK stock opened at GBX 1,628.22 ($21.28) on Wednesday. The business has a 50 day moving average of GBX 1,583.69. The company has a debt-to-equity ratio of 942.07, a quick ratio of 0.45 and a current ratio of 0.72. GlaxoSmithKline has a one year low of GBX 1,408.80 ($18.41) and a one year high of GBX 1,651 ($21.57). The firm has a market cap of $81.44 billion and a price-to-earnings ratio of 20.74.

In other GlaxoSmithKline news, insider Manvinder Singh Banga bought 458 shares of GlaxoSmithKline stock in a transaction on Wednesday, May 1st. The shares were bought at an average cost of GBX 1,568 ($20.49) per share, for a total transaction of £7,181.44 ($9,383.82). Over the last quarter, insiders have acquired 482 shares of company stock worth $755,935.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Article: What Does Beta Mean In Stock Selection

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Liberum Capital Lowers Superdry  Price Target to GBX 500
Liberum Capital Lowers Superdry Price Target to GBX 500
Grafton Group  Rating Reiterated by Liberum Capital
Grafton Group Rating Reiterated by Liberum Capital
GlaxoSmithKline  Stock Rating Reaffirmed by Shore Capital
GlaxoSmithKline Stock Rating Reaffirmed by Shore Capital
Eland Oil & Gas  Rating Reiterated by Peel Hunt
Eland Oil & Gas Rating Reiterated by Peel Hunt
Serco Group  Price Target Raised to GBX 160 at UBS Group
Serco Group Price Target Raised to GBX 160 at UBS Group
Ten Entertainment Group’s  Buy Rating Reiterated at Liberum Capital
Ten Entertainment Group’s Buy Rating Reiterated at Liberum Capital


© 2006-2019 Ticker Report